EUS-FNB with or without on-site evaluation for the diagnosis of solid pancreatic lesions (FROSENOR): Protocol for a multicenter randomized non-inferiority trial. Issue 6 (June 2019)
- Record Type:
- Journal Article
- Title:
- EUS-FNB with or without on-site evaluation for the diagnosis of solid pancreatic lesions (FROSENOR): Protocol for a multicenter randomized non-inferiority trial. Issue 6 (June 2019)
- Main Title:
- EUS-FNB with or without on-site evaluation for the diagnosis of solid pancreatic lesions (FROSENOR): Protocol for a multicenter randomized non-inferiority trial
- Authors:
- Crinò, Stefano Francesco
Manfrin, Ermina
Scarpa, Aldo
Baldaque-Silva, Francisco
Carrara, Silvia
De Nucci, Germana
Di Mitri, Roberto
Ginés, Angel
Iglesias-Garcia, Julio
Itoi, Takao
Kitano, Masayuki
Nguyen, Nam Quoc
Deprez, Pierre H.
Poley, Jan-Werner
Shami, Vanessa M.
Tarantino, Ilaria
Larghi, Alberto - Abstract:
- Abstract: Background: Rapid on-site evaluation (ROSE) of cytological specimensacquired with EUS-guided fine needle aspiration (EUS-FNA) represents the most accurate available technique to reach a definitive diagnosis in patients with pancreatic solid masses. Recently, needles with high histological yield have been developed for EUS-guided fine needle biopsy (EUS-FNB), with which the need for ROSE can be potentially overcome. Aims: The primary aim is to compare the diagnostic accuracy of EUS-FNB with or without ROSE. The main endpoint will be measured against the gold standard diagnosis (surgical pathology whenever available or diagnostic work-up in agreement with a clinical course of at least six months). Secondary endpoints include: (a) safety; (b) presence of tissue core; (c) quality of specimens; (d) time of the sampling procedure. Reliability of macroscopic on-site evaluation (MOSE) by endosonographers will be also assessed. Methods: FROSENOR is an international randomized non-inferiority ongoing study at sixteen centers in four continents. Eight hundred patients will be randomized in two arms (EUS-FNB + ROSE vs. EUS-FNB alone) and outcomes compared. Sample size has been calculated in order to demonstrate the non-inferiority of FNB alone. Randomization and data collection will be performed online. Discussion: This study will ascertain if ROSE is still needed when performing EUS-FNB of solid pancreatic lesions.
- Is Part Of:
- Digestive and liver disease. Volume 51:Issue 6(2019)
- Journal:
- Digestive and liver disease
- Issue:
- Volume 51:Issue 6(2019)
- Issue Display:
- Volume 51, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 51
- Issue:
- 6
- Issue Sort Value:
- 2019-0051-0006-0000
- Page Start:
- 901
- Page End:
- 906
- Publication Date:
- 2019-06
- Subjects:
- Diagnostic accuracy -- Endoscopic ultrasound -- Pancreatic cancer
Digestive organs -- Diseases -- Periodicals
Liver -- Diseases -- Periodicals
616.33005 - Journal URLs:
- http://www.sciencedirect.com/science/journal/15908658 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.dld.2019.03.008 ↗
- Languages:
- English
- ISSNs:
- 1590-8658
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3588.345600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 10597.xml